Clinical Trials on Eosinophilia in Hong Kong

Total 11 results

Allakos Inc.

Withdrawn

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA-SC)

Eosinophilic Gastritis | Eosinophilic Duodenitis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Asthma

United States
GlaxoSmithKline

Completed

Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients

Asthma

United States, Argentina, Australia, Canada, France, Germany, Japan, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Spain, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Eosinophilic Asthma

United States, Argentina, Brazil, Canada, France, Mexico, Germany, Greece, Korea, Republic of, Peru, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
GlaxoSmithKline

Completed

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

Asthma

United States, Argentina, Canada, France, Netherlands, Spain, Ukraine, Bulgaria, Estonia, Belgium, Peru, Russian Federation, Germany, Greece, Czechia, Italy, United Kingdom, Norway, Slovakia
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand, Argentina, Brazil, Canada, France, Mexico, Netherlands, Ge... and more
GlaxoSmithKline

Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial (DESTINY)

Hypereosinophilic Syndrome

United States, Italy, Japan, Spain, Argentina, Belgium, China, Korea, Republic of, Czechia, Germany, Israel, Denmark, Poland, Brazil, Greece, Turkey, Mexico, Australia, Hong Kong, Romania, United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes

Secondary Acute Myeloid Leukemia | Childhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic... and other conditions

United States, Canada, Australia, Puerto Rico
National Cancer Institute (NCI)

Completed

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and other conditions

United States, Canada, Australia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

Asthma | Elevated Blood Eosinophils | Oral Corticosteroid Dependence

United States, Argentina, Australia, Belgium, Czechia, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Russian Federation, Spain, Ukraine
Novartis Pharmaceuticals

Completed

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Hypereosinophilic Syndrome | Chronic Myelogenous Leukemia | Systemic Mastocytosis | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

United States, Poland, Italy, Belgium, Canada, France, Australia, Netherlands, Sweden, Switzerland, United Kingdom, Spain, Korea, Republic of, Austria, Germany, Denmark, Finland, Singapore, Taiwan, Hong Kong, New Zealand, Norway

Clinical Trials on Eosinophilia in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations